title: [Ebola and Marburg hemorrhagic fever viruses: update on filoviruses].
abstract: The Ebola and Marburg viruses are the sole members of the Filoviridae family of viruses. They are characterized by a long filamentous form that is unique in the viral world. Filoviruses are among the most virulent pathogens currently known to infect humans. They cause fulminating disease characterized by acute fever followed by generalized hemorrhagic syndrome that is associated with 90% mortality in the most severe forms. Epidemic outbreaks of Marburg and Ebola viruses have taken a heavy toll on human life in Central Africa and devastated large ape populations in Gabon and Republic of Congo. Since their discovery in 1967 (Marburg) and 1976 (Ebola), more than 2,300 cases and 1,670 deaths have been reported. These numbers pale in comparison with the burden caused by malnutrition or other infectious disease scourges in Africa such as malaria, cholera, AIDS, dengue or tuberculosis. However, due to their extremely high lethality, association with multifocal hemorrhaging and specificity to the African continent, these hemorrhagic fever viruses have given rise to great interest on the part not only of the international scientific community but also of the general public because of their perceived potential as biological weapons. Much research has been performed on these viruses and major progress has been made in knowledge of their ecology, epidemiology and physiopathology and in development of vaccine candidates and therapeutic schemes. The purpose of this review is to present the main developments in these particular fields in the last decade.
authors.affiliation: Centre International de Recherches Médicales de Franceville, Franceville, Gabon. eric.leroy@ird.fr
authors.forename: E
authors.initials: E
authors.lastname: Leroy
authors.forename: S
authors.initials: S
authors.lastname: Baize
authors.forename: J P
authors.initials: JP
authors.lastname: Gonzalez
mesh_terms: D000810:Angola / Q000453:epidemiology; D000818:Animals; D007560:Cote d'Ivoire / Q000453:epidemiology; D015023:Democratic Republic of the Congo / Q000453:epidemiology; D046129:Ebola Vaccines / Q000008:administration & dosage / Q000276:immunology; D029043:Ebolavirus / Q000302:isolation & purification* / Q000472:pathogenicity; D016563:Filoviridae / Q000302:isolation & purification; D005681:Gabon / Q000453:epidemiology; D019142:Hemorrhagic Fever, Ebola / Q000175:diagnosis* / Q000453:epidemiology* / Q000276:immunology / Q000401:mortality / Q000517:prevention & control; D006801:Humans; D015994:Incidence; D007630:Kenya / Q000453:epidemiology; D008379:Marburg Virus Disease / Q000175:diagnosis* / Q000453:epidemiology* / Q000276:immunology / Q000401:mortality / Q000517:prevention & control; D029024:Marburgvirus / Q000302:isolation & purification* / Q000472:pathogenicity; D015995:Prevalence; D013019:South Africa / Q000453:epidemiology; D013397:Sudan / Q000453:epidemiology; D014454:Uganda / Q000453:epidemiology; D014765:Viral Vaccines / Q000008:administration & dosage / Q000276:immunology
chemical_list: D046129:Ebola Vaccines; D014765:Viral Vaccines